Lexicon Pharmaceuticals to Present at the 26th Annual JPMorgan Healthcare Conference
January 03 2008 - 6:30AM
PR Newswire (US)
THE WOODLANDS, Texas, Jan. 3 /PRNewswire-FirstCall/ -- Lexicon
Pharmaceuticals, Inc. (NASDAQ:LXRX) announced today that Arthur T.
Sands, M.D., Ph.D., Lexicon's president and chief executive
officer, will present at the JPMorgan Healthcare Conference at The
Westin St. Francis Hotel in San Francisco, California on Thursday,
January 10, 2008 at 9:30 a.m. Pacific Time. Dr. Sands will provide
an overview of Lexicon's clinical and preclinical development
programs and corporate objectives. A live webcast of Lexicon's
presentation may be accessed on its corporate website at
http://www.lexpharma.com/. An archived version of the webcast will
be available on the website through January 18, 2008. About Lexicon
Lexicon is a biopharmaceutical company focused on the discovery and
development of breakthrough treatments for human disease. Lexicon
currently has development programs underway for such areas of major
unmet medical need as irritable bowel syndrome, cognitive
disorders, and autoimmune diseases. The company has used its
proprietary gene knockout technology to discover more than 100
promising drug targets and create an extensive pipeline of clinical
and preclinical programs in the therapeutic areas of diabetes and
obesity, cardiovascular disease, psychiatric and neurological
disorders, cancer, immune system disorders and ophthalmic disease.
To advance the development and commercialization of its programs,
Lexicon is working both independently and through collaborators
including Bristol-Myers Squibb Company, Genentech, Inc. and N.V.
Organon. For additional information about Lexicon and its programs,
please visit http://www.lexpharma.com/. Safe Harbor Statement This
press release contains "forward-looking statements," including
statements relating to Lexicon's growth and future operating
results, discovery and development of products, strategic alliances
and intellectual property, as well as other matters that are not
historical facts or information. All forward-looking statements are
based on management's current assumptions and expectations and
involve risks, uncertainties and other important factors that may
cause Lexicon's actual results to be materially different from any
future results expressed or implied by such forward-looking
statements. Information identifying such important factors is
contained under "Factors Affecting Forward-Looking Statements" and
"Risk Factors" in Lexicon's annual report on Form 10-K for the year
ended December 31, 2006, as filed with the Securities and Exchange
Commission. Lexicon undertakes no obligation to update or revise
any such forward-looking statements, whether as a result of new
information, future events or otherwise. DATASOURCE: Lexicon
Pharmaceuticals, Inc. CONTACT: Bobbie Faulkner, Manager, Investor
and Public Relations of Lexicon Pharmaceuticals, Inc.,
+1-281-863-3503, Web site: http://www.lexpharma.com/
Copyright
Lexicon Pharmaceuticals (NASDAQ:LXRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lexicon Pharmaceuticals (NASDAQ:LXRX)
Historical Stock Chart
From Jul 2023 to Jul 2024